[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635104":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":32,"responsibleParty":161,"collaborators":26,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":168,"sex":174,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":26,"studyType":180,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":190,"whyStopped":26,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Middle East North Africa Stroke and Interventional Neurotherapies Organization","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Endovascular Thrombectomy Plus Anticoagulation","EXPERIMENTAL","Participants in this arm will receive endovascular thrombectomy (EVT) within 24 hours of randomization, in addition to standard anticoagulation therapy. EVT techniques may include mechanical thrombectomy, aspiration thrombectomy, or balloon-assisted techniques at the discretion of the treating interventionalist. Standard anticoagulation consists of intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin, followed by oral anticoagulation for 3-12 months per guidelines.",[13,14],"Procedure: Endovascular Thrombectomy","Drug: Anticoagulation Therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Anticoagulation Alone","ACTIVE_COMPARATOR","Participants in this arm will receive standard anticoagulation therapy alone. Treatment consists of intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin during the acute phase, followed by oral anticoagulation (warfarin or direct oral anticoagulants) for 3-12 months as per current guidelines. No endovascular intervention will be performed.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Endovascular Thrombectomy","Endovascular thrombectomy (EVT) performed within 24 hours of randomization. Techniques include mechanical thrombectomy using stent retrievers, aspiration thrombectomy, balloon-assisted thrombectomy, or a combination approach at the discretion of the treating neurointerventionalist. The procedure is performed under general anesthesia or conscious sedation via femoral venous access with navigation to the affected cerebral venous sinus.",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"DRUG","Anticoagulation Therapy","Standard anticoagulation therapy consisting of intravenous unfractionated heparin (UFH) or subcutaneous low-molecular-weight heparin (LMWH) during the acute phase, followed by oral anticoagulation with warfarin (target INR 2.0-3.0) or direct oral anticoagulants (DOACs) for 3-12 months as per current AHA\u002FASA and ESO guidelines. Both arms receive this intervention.",[16,9],[33,50,58,63,68,78,88,98,108,118,126,134,144,153],{"facility":34,"status":26,"city":35,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Alexandria University, Smouha Comprehensive Stroke Center","Alexandria","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],29.91582,31.20176,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":26,"email":49},"Ossama Mansour, MD, PhD","CONTACT","+20-3-4282929","ossama.mansour@alexmed.edu.eg",{"facility":51,"status":26,"city":52,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":53,"geoPoint":57,"contacts":26},"Ain Shams University","Cairo",{"type":39,"coordinates":54},[55,56],31.24967,30.06263,{"lat":56,"lon":55},{"facility":59,"status":26,"city":52,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":60,"geoPoint":62,"contacts":26},"Cairo University",{"type":39,"coordinates":61},[55,56],{"lat":56,"lon":55},{"facility":64,"status":26,"city":52,"state":26,"zip":26,"country":36,"countryCode":37,"cosmosGeoPoint":65,"geoPoint":67,"contacts":26},"Neurology Department, Al-Azhar University",{"type":39,"coordinates":66},[55,56],{"lat":56,"lon":55},{"facility":69,"status":26,"city":70,"state":26,"zip":26,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":26},"Amman Specialized IR Center","Amman","Jordan","JO",{"type":39,"coordinates":74},[75,76],35.94503,31.95522,{"lat":76,"lon":75},{"facility":79,"status":26,"city":80,"state":26,"zip":26,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":26},"Centre Hospitalier Universitaire Ibn Sina de Rabat","Rabat","Morocco","MA",{"type":39,"coordinates":84},[85,86],-6.83255,34.01325,{"lat":86,"lon":85},{"facility":89,"status":26,"city":90,"state":26,"zip":26,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":26},"Aga Khan University","Karachi","Pakistan","PK",{"type":39,"coordinates":94},[95,96],67.0104,24.8608,{"lat":96,"lon":95},{"facility":99,"status":26,"city":100,"state":26,"zip":26,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":107,"contacts":26},"Weill Cornell Medicine-Qatar","Doha","Qatar","QA",{"type":39,"coordinates":104},[105,106],51.53096,25.28545,{"lat":106,"lon":105},{"facility":109,"status":26,"city":110,"state":26,"zip":26,"country":111,"countryCode":112,"cosmosGeoPoint":113,"geoPoint":117,"contacts":26},"King Khalid University","Abhā","Saudi Arabia","SA",{"type":39,"coordinates":114},[115,116],42.50528,18.21639,{"lat":116,"lon":115},{"facility":119,"status":26,"city":120,"state":26,"zip":26,"country":111,"countryCode":112,"cosmosGeoPoint":121,"geoPoint":125,"contacts":26},"King Abdulaziz Medical City","Jeddah",{"type":39,"coordinates":122},[123,124],39.18624,21.49012,{"lat":124,"lon":123},{"facility":127,"status":26,"city":128,"state":26,"zip":26,"country":111,"countryCode":112,"cosmosGeoPoint":129,"geoPoint":133,"contacts":26},"King Abdullah Medical City","Mecca",{"type":39,"coordinates":130},[131,132],39.82563,21.42664,{"lat":132,"lon":131},{"facility":135,"status":26,"city":136,"state":26,"zip":26,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":26},"Institut National de Neurologie","Tunis","Tunisia","TN",{"type":39,"coordinates":140},[141,142],10.16579,36.81897,{"lat":142,"lon":141},{"facility":145,"status":26,"city":146,"state":26,"zip":26,"country":147,"countryCode":26,"cosmosGeoPoint":148,"geoPoint":152,"contacts":26},"Department of Neurology, Eskisehir Osmangazi University","Eskişehir","Turkey (Türkiye)",{"type":39,"coordinates":149},[150,151],30.52056,39.77667,{"lat":151,"lon":150},{"facility":154,"status":26,"city":155,"state":26,"zip":26,"country":147,"countryCode":26,"cosmosGeoPoint":156,"geoPoint":160,"contacts":26},"Neurology Department, Dr. Lutfi Kirdar City Hospital","Istanbul",{"type":39,"coordinates":157},[158,159],28.94966,41.01384,{"lat":159,"lon":158},{"type":162,"investigatorFullName":163,"investigatorTitle":164,"investigatorAffiliation":165,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Ossama Mansour","Professor of Neurology, Alexandria University","Alexandria University","100635104","mena-regional-endovascular-intervention-for-venous-cerebral-venous-sinus-thrombosis-100635104",false,"NCT07548346","MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis","REVIVE-CVST: A Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint (PROBE) Trial of Endovascular Thrombectomy Plus Standard Medical Care Versus Standard Medical Care Alone in Adults With Acute or Subacute Cerebral Venous Sinus Thrombosis at High Risk of Poor Outcome in the Middle East and North Africa Region","REVIVE-CVST","Inclusion Criteria:\n\n* Age 18-65 years, inclusive\n* Radiologically confirmed cerebral venous sinus thrombosis (CVST) by CT venography (CTV), MR venography (MRV), or digital subtraction angiography (DSA), with thrombosis of at least one major dural sinus\n* Acute or subacute presentation with symptom onset within 21 days of randomization\n* MRI phase characterization confirming acute or subacute phase\n* At least one risk factor for poor outcome: symptoms of intracranial hypertension (severe headache, papilledema, visual obscurations), focal neurological deficit, seizures, altered consciousness (GCS 9-14), intracranial hemorrhage from venous congestion, or deep venous system thrombosis\n* Significant venous outflow obstruction on imaging\n* Written informed consent from patient or legally authorized representative\n\nExclusion Criteria:\n\n* Isolated cortical vein thrombosis without dural sinus involvement\n* Isolated cavernous sinus thrombosis\n* Chronic-phase CVST on MRI phase characterization\n* Pre-morbid modified Rankin Scale (mRS) score greater than 2\n* Glasgow Coma Scale (GCS) score less than 9 at randomization\n* Imminent risk of transtentorial herniation requiring emergent decompressive craniectomy\n* Massive cerebral edema with midline shift greater than 10 mm requiring surgical intervention\n* Active systemic bleeding or hemorrhagic diathesis\n* Severe allergy to iodinated contrast media\n* CVST secondary to active hematological malignancy or life expectancy less than 12 months\n* Pregnancy\n* Participation in another interventional clinical trial within 30 days\n* Any condition rendering the patient unsuitable for study participation per investigator judgment","ALL","18 Years","65 Years",{"count":178,"type":179},440,"ESTIMATED","INTERVENTIONAL",[182],"NA","REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to anticoagulation alone in patients with severe cerebral venous sinus thrombosis (CVST).\n\nThe study targets adult patients (aged 18 years or older) presenting within 14 days of symptom onset with imaging-confirmed CVST and at least one severity marker, such as a Glasgow Coma Scale score of 14 or below, intracerebral hemorrhage, venous infarction, or deep venous system involvement.\n\nParticipants will be randomly assigned in a 1:1 ratio to either the intervention arm (EVT plus anticoagulation) or the control arm (anticoagulation alone). The primary endpoint is functional outcome at 180 days as measured by the modified Rankin Scale (mRS), using a shift analysis across all mRS categories.\n\nThe trial aims to enroll 440 participants across approximately 15 centers in the Middle East, North Africa, South Asia, and Turkey (MENA-SINO network). The study duration is approximately 42 months, including 18 months of enrollment and 12 months of follow-up for the last enrolled patient.",[185],"Cerebral Venous Sinus Thrombosis",[187,188,189],"CVST","endovascular thrombectomy","anticoagulation","NOT_YET_RECRUITING","2026-04-16",{"date":193,"type":194},"2026-04-23","ACTUAL",{"date":196,"type":179},"2026-07",{"date":198,"type":179},"2030-01",{"name":5,"class":6},14]